Proportions of Proinflammatory Monocytes Are Important Predictors of Mortality Risk in Hemodialysis Patients
| Autor: | Paik Seong Lim, Yachung Jeng, Chang Hsu Chen, Ming Ying Wu, Tsai-Kun Wu, Hung Ping Chen, Tien-Yu Tseng |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Article Subject medicine.medical_treatment Immunology Lipopolysaccharide Receptors 030232 urology & nephrology MEDLINE Kaplan-Meier Estimate Disease 030204 cardiovascular system & hematology Monocytes Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine Renal Dialysis Internal medicine lcsh:Pathology Humans Medicine Intensive care medicine Dialysis business.industry Receptors IgG Cell Biology Cardiovascular Diseases Female Hemodialysis business lcsh:RB1-214 Research Article |
| Zdroj: | Mediators of Inflammation Mediators of Inflammation, Vol 2017 (2017) |
| ISSN: | 1466-1861 0962-9351 |
| DOI: | 10.1155/2017/1070959 |
| Popis: | Despite the continuous progression in dialysis medicine, mortality and the burden of cardiovascular disease (CVD) among hemodialysis patients are still substantial. Substantial evidence suggests that proinflammatory (CD16+) monocytes contribute to the development of atherosclerosis. A cohort of 136 stable hemodialysis patients (follow-up: 6.25 year) was assessed to investigate the association between the proportion of CD16+ monocytes for all-cause and CVD mortalities. The CD16+ monocytes were associated with both mortalities after adjusting for a preexisting CVD history. Compared to the reference group (CD16+ monocytes within [15.6–18.6], the first and second quartile), patients with CD16+ monocytes above the highest quartile level (>21.5) had an adjusted hazard ratio (HR) of 30.85 (95% confidence interval [CI]: 7.12–133.8) for CVD mortality and 5.28 (2.07–13.49) for all-cause mortality, and those with CD16+ monocytes below the lowest quartile ≤15.6), had significantly elevated death risks after 3.5-year follow-up (HR [95% CI]: 10.9 [2.42–48.96] and 4.38 [1.45–13.24] for CV and all-cause mortalities, respectively). The hemodialysis patients with CD16+ monocyte level in a low but mostly covering normal range also portended a poor prognosis. The findings shed some light for nephrologists on future prospects of early recognizing immune dysfunction and improving early intervention outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|